MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. [electronic resource]
Producer: 20101007Description: 6880-90 p. digitalISSN:- 1538-7445
- Animals
- Carcinoma -- drug therapy
- Cell Cycle -- drug effects
- Cell Growth Processes -- drug effects
- Drug Synergism
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Female
- Hepatocyte Growth Factor -- metabolism
- Humans
- Mice
- Mice, Inbred C3H
- Mice, SCID
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-met -- antagonists & inhibitors
- Pyridazines -- pharmacology
- Quinazolines -- pharmacology
- Receptors, Growth Factor -- antagonists & inhibitors
- Triazoles -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.